| 1. |
|
|
| 2. |
- van Ree, R, et al.
(författare)
-
The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification.
- 2008
-
Ingår i: Allergy. - : Wiley. - 1398-9995 .- 0105-4538. ; 63:3, s. 310-26
-
Tidskriftsartikel (refereegranskat)abstract
- Allergen extracts have been used for diagnosis and treatment of allergy for around 100 years. During the second half of 20th century, the notion increasingly gained foothold that accurate standardization of such extracts is of great importance for improvement of their quality. As a consequence, manufacturers have implemented extensive protocols for standardization and quality control. These protocols have overall IgE-binding potencies as their focus. Unfortunately, each company is using their own in-house reference materials and their own unique units to express potencies. This does not facilitate comparison of different products. During the last decades, most major allergens of relevant allergen sources have been identified and it has been established that effective immunotherapy requires certain minimum quantities of these allergens to be present in the administered maintenance dose. Therefore, the idea developed to introduce major allergens measurements into standardization protocols. Such protocols based on mass units of major allergen, quantify the active ingredients of the treatment and will at the same time allow comparison of competitor products. In 2001, an EU funded project, the CREATE project, was started to support introduction of major allergen based standardization. The aim of the project was to evaluate the use of recombinant allergens as reference materials and of ELISA assays for major allergen measurements. This paper gives an overview of the achievements of the CREATE project.
|
|
| 3. |
- Aalto, Susanne, 1964, et al.
(författare)
-
High-resolution HNC 3-2 SMA observations of Arp 220
- 2009
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 493:2, s. 481-487
-
Tidskriftsartikel (refereegranskat)abstract
- Aims. We study the properties of the nuclear molecular gas of the ultra luminous merger Arp 220 and effects of the nuclear source on gas excitation and chemistry. Specifically, our aim is to investigate the spatial location of the luminous HNC 3-2 line emission and address the underlying cause of its unusual brightness.Methods. We present high resolution observations of HNC J=3-2 with the submillimeter array (SMA).Results. We find luminous HNC 3-2 line emission in the western part of Arp 220, centred on the western nucleus, while the eastern side of the merger shows relatively faint emission. A bright (36 K at $0\hbox{$.\!\!^{\prime\prime}$ }4$ resolution), narrow (60 ${\rm km~s}^$) emission feature emerges from the western nucleus, superposed on a broader spectral component. A possible explanation is weak maser emission through line-of-sight amplification of the background continuum source. There is also a more extended HNC 3-2 emission feature north and south of the nucleus. This feature resembles the bipolar OH maser morphology around the western nucleus. Substantial HNC abundances are required to explain the bright line emission from this warm environment - even when the high gas column density towards the western nucleus is taken into account. We discuss this briefly in the context of an X-ray affected chemistry and radiative excitation.Conclusions. The luminous and possibly amplified HNC emission of the western nucleus of the Arp 220 merger reflects the unusual, and perhaps transient environment of the starburst/AGN activity there. The faint HNC line emission towards Arp 220-east reveals a real difference in physical conditions between the two merger nuclei.
|
|
| 4. |
- Capella, Gabriel, et al.
(författare)
-
DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study
- 2008
-
Ingår i: International Journal of Epidemiology. - : Oxford University Press (OUP). - 1464-3685 .- 0300-5771. ; 37:6, s. 1316-1325
-
Tidskriftsartikel (refereegranskat)abstract
- Background The contribution of genetic variation in DNA repair genes to gastric cancer (GC) risk remains essentially unknown. The aim of this study was to explore the relative contribution of DNA repair gene polymorphisms to GC risk and severe chronic atrophic gastritis (SCAG). Method A nested case control study within the EPIC cohort was performed including 246 gastric adenocarcinomas and 1175 matched controls. Controls with SCAG (n 91), as defined by low pepsinogen A (PGA) levels, and controls with no SCAG (n 1061) were also compared. Twelve polymorphisms at DNA repair genes (MSH2, MLH1, XRCC1, OGG1 and ERCC2) and TP53 gene were analysed. Antibodies against Helicobacter pylori were measured. Results No association was observed for any of these polymorphisms with stomach cancer risk. However, ERCC2 K751Q polymorphism was associated with an increased risk for non-cardial neoplasm [odds ratio (OR) 1.78; 95 confidence interval (CI) 1.023.12], being ERCC2 K751Q and D312N polymorphisms associated with the diffuse type. ERCC2 D312N (OR 2.0; 95 CI 1.093.65) and K751Q alleles (OR 1.82; 95 CI 1.013.30) and XRCC1 R399Q (OR 1.69; 95 CI 1.022.79) allele were associated with an increased risk for SCAG. Conclusion Our study supports a role of ERCC2 in non-cardial GC but not in cardial cancer. A concordant result was observed for subjects with low PGA levels. XRCC1 allele was associated also with SCAG. This is the first prospective study suggesting that individual variation in DNA repair may be relevant for gastric carcinogenesis, a finding that will require further confirmation validation in larger independent studies.
|
|
| 5. |
|
|
